Logan A, Smith C, Becks G P, Gonzalez A M, Phillips I D, Hill D J
Department of Clinical Chemistry, University of Birmingham, UK.
J Endocrinol. 1994 Apr;141(1):45-57. doi: 10.1677/joe.0.1410045.
Transforming growth factor-beta 1 (TGF-beta 1) has been reported to influence the growth rate and iodine uptake and organification in vitro by isolated thyrocytes. We have determined changes in the expression and presence of TGF-beta 1 within the rat thyroid during goitre induction, and subsequent involution following goitrogen withdrawal. Hyperplastic goitres were induced in adult rats by administration of methimazole together with a low iodine diet for up to 12 weeks. Goitrogen-treated rats quickly became hypothyroid compared with controls, and exhibited thyroid hyperplasia and hypertrophy assessed by thyroid weight, and DNA and protein content (control: total serum thyroxine (T4) 66 +/- 4 nmol/l, thyroid weight 5 +/- 1 mg/100 g body weight, mean +/- S.D., n = 10; 2 weeks goitrogen: T4 undetectable, thyroid weight 27 +/- 4 mg/100 g, n = 10). Thyroid growth rate slowed subsequently between 2 and 10 weeks. Messenger RNA for TGF-beta 1 was compared in the thyroids and livers of control and goitrous rats by ribonuclease protection assay. Low levels of mRNA for TGF-beta 1 were detected in thyroids from control rats at all time-points, while TGF-beta 1 mRNA was barely detectable in liver. Thyroid TGF-beta 1 mRNA levels substantially and progressively increased at 1 and 2 weeks of goitrogen treatment respectively, and remained above control levels at 4 and 10 weeks. As thyroid involution occurred 4 weeks following goitrogen withdrawal, so thyroid TGF-beta 1 mRNA levels declined. In control animals, the cellular localization of TGF-beta 1 mRNA, determined by in situ hybridization, was found to be a subpopulation of follicular epithelial cells, and immunohistochemical co-localization of TGF-beta 1 and calcitonin identified these tentatively as parafollicular or C-cells. During goitre formation, abundant TGF-beta 1 mRNA and peptide were found to be widely distributed within the entire follicular epithelium. While this ubiquitous distribution had largely disappeared in the involuting gland, TGF-beta 1 peptide was retained within the parafollicular cells, which appeared more abundant than in thyroids from control animals. These results suggest that an increased local expression of TGF-beta 1, a putative growth inhibitor, during thyroid hyperplasia may contribute to the temporal stabilization of goitre size.
据报道,转化生长因子β1(TGF-β1)可影响体外分离的甲状腺细胞的生长速率、碘摄取及有机化过程。我们已确定在大鼠甲状腺肿诱导期间以及随后撤掉致甲状腺肿物质后的退化过程中,TGF-β1表达及存在情况的变化。通过给予甲巯咪唑并搭配低碘饮食,对成年大鼠进行长达12周的处理,以诱导增生性甲状腺肿。与对照组相比,接受致甲状腺肿物质处理的大鼠很快出现甲状腺功能减退,并通过甲状腺重量、DNA和蛋白质含量评估显示出甲状腺增生和肥大(对照组:血清总甲状腺素(T4)66±4 nmol/L,甲状腺重量5±1 mg/100 g体重,平均值±标准差,n = 10;致甲状腺肿物质处理2周:T4检测不到,甲状腺重量27±4 mg/100 g,n = 10)。随后在2至10周期间,甲状腺生长速率减缓。通过核糖核酸酶保护试验比较了对照组和甲状腺肿大鼠甲状腺及肝脏中TGF-β1的信使核糖核酸(mRNA)。在所有时间点,对照组大鼠甲状腺中均检测到低水平的TGF-β1 mRNA,而在肝脏中几乎检测不到TGF-β1 mRNA。在致甲状腺肿物质处理1周和2周时,甲状腺TGF-β1 mRNA水平分别大幅且逐渐升高,并在4周和10周时仍高于对照水平。随着撤掉致甲状腺肿物质后4周甲状腺发生退化,甲状腺TGF-β1 mRNA水平下降。在对照动物中,通过原位杂交确定TGF-β1 mRNA的细胞定位为滤泡上皮细胞的一个亚群,并且TGF-β1与降钙素的免疫组织化学共定位初步将这些细胞确定为滤泡旁细胞或C细胞。在甲状腺肿形成过程中,发现丰富的TGF-β1 mRNA和肽广泛分布于整个滤泡上皮内。虽然这种普遍分布在退化的腺体中已基本消失,但TGF-β1肽保留在滤泡旁细胞内,这些细胞看起来比对照动物的甲状腺中的更为丰富。这些结果表明,在甲状腺增生期间,一种假定的生长抑制剂TGF-β1的局部表达增加可能有助于甲状腺肿大小的暂时稳定。